Abbott And Teva Settle Fight Over Biaxin
In documents filed Monday, the two companies asked the court to dismiss the case.
Terms of the settlement were not disclosed in court documents. Whether the settlement changes plans Teva had to sell a generic version of Biaxin remains unclear.
Jonathon Hamilton, a spokesperson for Abbott, said the terms were confidential and that he couldn’t say whether the settlement affects Teva’s sale...
To view the full article, register now.